Browse articles from EyeWorld.org related to sustained release. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
In his introduction to the “Interventional glaucoma” bonus issue of EyeWorld, Chief Medical Editor Sumit “Sam” Garg, MD, shared some of his personal experiences in this space and what topics readers can expect to learn more about.
While ophthalmologists agree that glaucoma drops are not likely to go extinct as part of glaucoma management, recent innovation continues to shift their place in many physicians’ glaucoma treatment algorithm. One of these disruptive innovations is sustained drug delivery. Two experts weighed in on the topic.
➤ NDA submitted for sustained-release travoprost implant ➤ BLA for wet AMD, DME, DR treatment accepted with priority review ➤ Topline results from 12-month safety clinical trial for investigational dry eye drug ➤ Companies collaborate for research on sustained release for investigational GA drug ➤ ASCRS news and events
Innovation is changing the philosophy of glaucoma treatment from a drop-dependent approach to an interventional, procedure-based approach, according to Savak Teymoorian, MD. Where he’s found the philosophy shift toward acceptance of interventional glaucoma among patients has been with Durysta (bimatoprost intracameral implant, Allergan).
Glaucoma Editor Nathan Radcliffe, MD, introduces the topics covered in the section, including early experience with Durysta, how other sustained therapies can benefit the glaucoma patient following cataract surgery, and how glaucoma care can be streamlined to keep everyone safe in the pandemic.
Durysta, the sustained-release bimatoprost implant, 10 mcg (Allergan), has been available with FDA approval in the U.S. market for a year now. EyeWorld spoke with two physicians who started offering it as an option to their patients to hear about their experience thus far.